STOCK TITAN

Oncolytics Biotech Inc Stock Price, News & Analysis

ONCY Nasdaq

Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.

Oncolytics Biotech Inc (ONCY) is a clinical-stage biotech company advancing pelareorep, an innovative oncolytic virus immunotherapy targeting multiple cancer types. This dedicated news hub provides investors and researchers with centralized access to corporate developments and scientific progress updates.

Track critical updates including clinical trial results, regulatory milestones, and strategic partnerships. Our curated collection features press releases spanning Phase 2 breast cancer studies, pancreatic cancer research advancements, and manufacturing capacity expansions. Regular updates ensure timely awareness of key developments in HR+/HER2- metastatic breast cancer trials and other high-priority programs.

Discover verified information on pelareorep's mechanism of action, trial design specifics, and intellectual property developments. The resource eliminates the need by aggregating essential updates from randomized controlled studies to manufacturing quality initiatives. Bookmark this page for efficient monitoring of Oncolytics' progress in transforming cancer treatment through viral immunotherapy approaches.

Rhea-AI Summary

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the completion of enrollment in the first dose escalation of a clinical trial evaluating pelareorep combined with paclitaxel for advanced breast cancer in China. There have been no reported safety issues, and the trial is progressing to its second cohort, which mirrors an earlier study showing improved survival rates. Results from this trial could facilitate future regulatory submissions in China, enhancing pelareorep's market potential in one of the largest pharmaceutical markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
none
-
Rhea-AI Summary

Oncolytics Biotech (NASDAQ: ONCY) updated on the phase 1/2 GOBLET study for pelareorep presented at the 2022 ASCO-GI symposium. The study evaluates pelareorep combined with Roche's atezolizumab in treating metastatic pancreatic, colorectal, and anal cancers. Enrollment for safety run-ins is complete at 14 sites in Germany. Prior studies suggest pelareorep may enhance responses to immune checkpoint inhibitors in GI cancers. The study aims to validate pelareorep's efficacy and identify potential biomarkers for patient selection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.65%
Tags
-
Rhea-AI Summary

Oncolytics Biotech (NASDAQ: ONCY) released a letter to shareholders reviewing 2021 achievements and outlining goals for 2022, particularly in developing pelareorep for metastatic breast cancer. The company highlighted a near doubling of overall survival in HR+/HER2- breast cancer patients and progress in clinical trials. Key objectives include confirming pelareorep's mechanisms, assessing synergy with immune checkpoint inhibitors, and identifying biomarkers for patient selection. Upcoming milestones include full enrollment in BRACELET-1 and top-line data release expected in Q4 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
none
Rhea-AI Summary

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the promotion of Dr. Thomas C. Heineman to Chief Medical Officer. Dr. Heineman brings over two decades of clinical development experience, having previously served as Global Head of Clinical Development at Oncolytics. His role will focus on the advancement of the company's lead program for metastatic breast cancer and the ongoing development of pelareorep, an immunotherapeutic agent. This compound aims to induce immune responses against cancer and is currently being evaluated in combination with other therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
-
Rhea-AI Summary

Oncolytics Biotech has announced promising preclinical results showing that the combination of pelareorep and azacitidine significantly reduces tumor burden in acute myeloid leukemia (AML) cells. Data presented at the 2021 American Society of Hematology Annual Meeting indicates a p<0.01 reduction in tumor burden and a p<0.001 enhancement of anti-leukemic activity compared to individual treatments. The combination also upregulated genes driving immune responses, highlighting pelareorep's potential across various blood cancers. The company aims to expand research into leukemia and other malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
-
Rhea-AI Summary

Oncolytics Biotech presented a positive interim safety update from the investigator-sponsored Phase 2 IRENE trial at the 2021 San Antonio Breast Cancer Symposium. This trial evaluates the combination of pelareorep and Incyte's retifanlimab for treating metastatic triple-negative breast cancer (TNBC). No safety concerns were reported among the five enrolled patients. The study aims to assess both safety and efficacy, focusing on PD-L1 expression changes, which might identify patients likely to respond to therapy. The trial continues at key cancer institutes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
Rhea-AI Summary

Oncolytics Biotech will present updates on the Phase 2 IRENE trial for treating metastatic triple-negative breast cancer (TNBC) at the 2021 San Antonio Breast Cancer Symposium from December 7-10, 2021. The study evaluates the combination of pelareorep and Incyte's anti-PD-1 inhibitor, retifanlimab, on 25 patients. This open-label trial focuses on safety and response rates, with secondary endpoints including progression-free survival and overall survival. The IRENE trial is crucial in advancing pelareorep as a potential treatment option in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
conferences clinical trial
-
Rhea-AI Summary

Oncolytics Biotech reported significant advancements in its pelareorep development programs, particularly in breast and gastrointestinal cancers. The AWARE-1 study suggested blood T cell changes could predict therapy response, enhancing future patient selection. The company also initiated the GOBLET trial in collaboration with Roche, targeting unmet needs in gastrointestinal cancers. Financially, Oncolytics holds approximately $48 million in cash, with a net loss of $4.9 million for Q3 2021, showing improvement from $6.7 million the previous year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
-
Rhea-AI Summary

Oncolytics Biotech (NASDAQ: ONCY) has initiated the phase 1/2 GOBLET trial, dosing the first patient to evaluate the safety and efficacy of the combination of pelareorep and Roche's atezolizumab in gastrointestinal cancers, including metastatic pancreatic, colorectal, and anal cancers. The trial, managed by AIO in Germany, aims to improve patient responses to immune checkpoint inhibitors, addressing the high unmet need in gastrointestinal cancer treatments. The GOBLET study follows promising earlier results, which suggest significant clinical benefits in related conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
Rhea-AI Summary

Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call on November 5, 2021, at 8:00 a.m. ET, to discuss third-quarter financial results and corporate updates. Investors can dial in North America at (888) 664-6383 or internationally at (416) 764-8650. The event will be webcast and archived on the company's Investor Relations page. Oncolytics is focused on developing pelareorep, an immunotherapeutic agent aimed at inducing immune responses against various cancers. The company is conducting clinical trials in combination with existing oncology treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
conferences earnings

FAQ

What is the current stock price of Oncolytics Biotech (ONCY)?

The current stock price of Oncolytics Biotech (ONCY) is $1.18 as of July 11, 2025.

What is the market cap of Oncolytics Biotech (ONCY)?

The market cap of Oncolytics Biotech (ONCY) is approximately 81.7M.
Oncolytics Biotech Inc

Nasdaq:ONCY

ONCY Rankings

ONCY Stock Data

81.71M
85.68M
4.35%
1.62%
3.44%
Biotechnology
Healthcare
Link
Canada
Calgary